Canada
· Delayed Price · Currency is CAD Restart Life Sciences Statistics
Total Valuation
Restart Life Sciences has a market cap or net worth of CAD 1.26 million. The enterprise value is 1.07 million.
| Market Cap | 1.26M |
| Enterprise Value | 1.07M |
Important Dates
The next estimated earnings date is Tuesday, April 8, 2025.
| Earnings Date | Apr 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Restart Life Sciences has 36.02 million shares outstanding. The number of shares has increased by 4.10% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 36.02M |
| Shares Change (YoY) | +4.10% |
| Shares Change (QoQ) | +3.49% |
| Owned by Insiders (%) | 8.33% |
| Owned by Institutions (%) | 5.82% |
| Float | 33.02M |
Valuation Ratios
The trailing PE ratio is 83.78.
| PE Ratio | 83.78 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 71.12 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.30
| Current Ratio | 0.30 |
| Quick Ratio | 0.30 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -219.74% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.00% in the last 52 weeks. The beta is 0.72, so Restart Life Sciences's price volatility has been lower than the market average.
| Beta (5Y) | 0.72 |
| 52-Week Price Change | -70.00% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.07 |
| Relative Strength Index (RSI) | 49.54 |
| Average Volume (20 Days) | 36,113 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Restart Life Sciences had revenue of CAD -28,346 and earned 15,049 in profits.
| Revenue | -28,346 |
| Gross Profit | -28,346 |
| Operating Income | -562,099 |
| Pretax Income | 15,049 |
| Net Income | 15,049 |
| EBITDA | -559,631 |
| EBIT | -562,099 |
| Earnings Per Share (EPS) | -0.00 |
Balance Sheet
The company has 250,593 in cash and 60,000 in debt, giving a net cash position of 190,593 or 0.01 per share.
| Cash & Cash Equivalents | 250,593 |
| Total Debt | 60,000 |
| Net Cash | 190,593 |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | -585,994 |
| Book Value Per Share | -0.02 |
| Working Capital | -595,644 |
Cash Flow
| Operating Cash Flow | -76,830 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | 1,982.99% |
| Pretax Margin | -53.09% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Restart Life Sciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.10% |
| Shareholder Yield | -4.10% |
| Earnings Yield | -3.61% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on November 8, 2024. It was a reverse split with a ratio of 0.2.
| Last Split Date | Nov 8, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
Restart Life Sciences has an Altman Z-Score of -319.07. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -319.07 |
| Piotroski F-Score | n/a |